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Management of idiopathic crescentic and diffuse proliferative may also be some overlap in etiology, the major causes
glomerulonephritis: Evidence-based recommendations. Idio- of necrotizing crescentic GN may now be separated from
pathic crescentic glomerulonephritis (GN) often presents with those of diffuse endocapillary proliferative GN. The nat-a rapid loss of renal function and pathology showing extensive
ural history and management of these two entities arecrescent formation. The disease is caused by different immuno-
also quite different.pathogenetic mechanisms, pauci-immune, often antineutrophil
cytoplasmic antibody (ANCA)-positive microvasculitis, anti- Rapidly progressive GN (RPGN) is discussed in detail
glomerular basement membrane (GBM) antibody disease, and because of the poor prognosis of untreated patients and
immune complex formation. Historical reviews reveal poor
recent advances in treatment. Idiopathic diffuse prolifer-renal prognosis, even after treatment with oral steroids and
ative GN is described more briefly. For both conditions,cytotoxic drugs. Prognosis has improved in the last decade. In
this article, evidence-based recommendations for management first the definition is outlined, and then the classification,
are presented. Because of the high risk of end-stage renal diagnosis, and pathology. Then, recommendations are
disease (ESRD), early aggressive therapy is recommended, offered for management, based on evidence from pub-
despite weak supporting evidence. Treatment for anti-GBM
lished studies. The studies were obtained from a compre-antibody-induced crescentic GN should be initiated early and
hensive literature search, followed by secondary searchesshould include pulse methylprednisolone, a two-week course
of plasmapheresis and two months of treatment with corticoste- as needed.
roids and cyclophosphamide (grade B and C). Treatment for
pauci-immune crescentic GN should be pulse methylpredniso-
lone, followed by oral corticosteroids and cyclophosphamide RAPIDLY PROGRESSIVE
for 6 to 12 months (grade B). Recurrences can be managed GLOMERULONEPHRITIS
similarly (grade B), along with appropriate supportive therapy.
Rapidly progressive GN is a clinicopathological entityIn patients who develop ESRD, successful transplantation can
be performed. Diffuse endocapillary proliferative GN is classi- characterized by a rapid loss of renal function (usually
cally postinfectious. It generally has a good prognosis when a 50% decline in glomerular filtration rate) within three
no crescent formation occurs. Adult patients with persistent
months, with the principal histological finding of exten-proteinuria, hypertension, and renal function impairment need
sive crescent formation (usually involving over 50% ofcareful follow-up and management to modify progressive he-
modynamic injury. the glomeruli) [1].
This disorder is usually due to one of three different
mechanisms of glomerular injury [2]. Anti-glomerular
This article deals with the evidence-based manage- basement membrane (anti-GBM) antibody disease is re-
ment of two conditions: crescentic glomerulonephritis sponsible for 10 to 20% of all patients with RPGN. When
(GN), a disease generally characterized by progressive associated with pulmonary hemorrhage, it is called Good-
deterioration in renal function, and diffuse endocapillary pasture’s syndrome.
proliferative GN without crescent formation, a condition A second mechanistic form of RPGN is immune com-
in which patients initially have severe renal dysfunction plex RPGN. This entity, which is responsible for approxi-
but most often recover and have an excellent long-term mately 40% of all cases of RPGN, can be due to one of
prognosis. Patients with crescentic GN and diffuse endo- a number of systemic diseases. These include postinfec-
capillary proliferation without crescent formation may tious GN, IgA nephropathy, Henoch-Scho¨nlein purpura,
have a similar initial clinical presentation. Although there lupus nephritis, membranous nephropathy, and membra-
noproliferative GN. A few cases of idiopathic immune
complex RPGN have been reported, but they seem toKey words: crescent formation, ANCA, microvasculitis, immune com-
plex, end-stage renal disease. follow a clinical course very similar to patients with
RPGN lacking immune deposits. It is possible that non- 1999 by the International Society of Nephrology
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specific immunoglobulin trapping may occur in some of pathology in various forms of RPGN is beyond the scope
these cases. of this article. Only the pathological findings that are
The final form of RPGN is pauci-immune RPGN, in helpful in the differential diagnosis of RPGN are dis-
which glomerular inflammation and necrosis are present cussed.
with few or no immune deposits. A large majority of pa- Immunohistology is most useful in categorizing differ-
tients with this disorder have antineutrophil cytoplasmic ent types of RPGN. Linear GBM localization of immu-
antibodies (ANCAs), and many have systemic symptoms noglobulin is indicative of anti-GBM antibody-mediated
of vasculitis. With the advent of ANCA testing, true disease. Ten to 20% of the patients presenting as RPGN
idiopathic RPGN may be a rare entity. have this pattern. Granular glomerular localization of
Clinical features common to the three forms of RPGN immunoglobulins and complement is indicative of im-
include hematuria, proteinuria, decreased urine output, mune complex-mediated diseases, and 30 to 40% of pa-
edema, and hypertension. Patients with anti-GBM anti- tients presenting as RPGN have this pattern. No or
body disease may also have pulmonary hemorrhage with scanty glomerular immunoglobulin localization occurs in
hemoptysis due to antibodies directed against the alveo- pauci-immune necrotizing crescentic GN. This pattern
lar basement membrane. Similar clinical findings can also is seen in 40 to 50% of all patients presenting as RPGN,
occur in microscopic polyarteritis and Wegener’s granu- whether clinically limited to renal involvement or part
lomatosis because of involvement of the vessels by the of a systemic vasculitis.
vasculitic process. Although breaks in GBMs may be observed on elec-
Patients with pauci-immune RPGN often have an in- tron microscopy in patients with RPGN, the major role
sidious onset with initial symptoms being fatigue, fever, of electron microscopy is in distinguishing the different
night sweats, and arthralgias, features similar to those in forms of immune complex-induced RPGN. Scattered
patients with systemic vasculitis. The urinalysis typically large subepithelial dense deposits are typical for post-
reveals hematuria, with dysmorphic red blood cells (RBC), streptococcal GN. Large subendothelial dense deposits
RBC casts, and variable degrees of proteinuria. Renal are seen in severe proliferative lupus nephritis. Large
insufficiency is common. mesangial deposits are more characteristic of IgA nephrop-
The first step in the management of RPGN is a rapid athy and Henoch-Scho¨nlein purpura-associated nephritis.
diagnosis. This requires distinguishing RPGN from other
causes of renal failure with acute onset and similar uri- Management of rapidly progressive glomerulonephritis
nary findings. These include acute interstitial nephritis, The treatment of RPGN can be divided into two parts:
thrombotic microangiopathies (including hemolytic ure-
the specific treatment against the inflammatory renal
mic syndrome, thrombotic thrombocytopenic purpura,
injury and the management of pathophysiological conse-acute postpartum renal failure, progressive systemic
quences of glomerular disease, such as fluid retention,scerlosis, and malignant hypertension), acute atheroscle-
hypertension, hyperkalemia, and uremia.rotic renal failure, and diffuse proliferative GN [2].
Specific therapy against renal inflammatory injury. FewIf clinical features point toward GN as a cause of
prospective controlled studies exist with sufficient num-rapidly progressive renal failure, the specific form of GN
ber of patients to allow strong conclusions regardingmust be identified in order to provide optimal therapy.
therapeutic benefits. Most available reports have usedClinical and laboratory features may be helpful in the
historical controls for comparison. The demonstrateddifferential diagnosis, but histological analysis of tissue
benefit in more recent series may be related to severalobtained by renal biopsy is the most important method
factors other than the effect of the specific treatment,for categorizing and staging this type of GN.
such as earlier diagnosis, recognition of milder cases, andThe purpose of laboratory tests is to help distinguish
improved management of related complications such asglomerular causes of acute renal failure, as well as the
fluid retention, hypertension, uremia, and infections.differential diagnosis among various causes of RPGN.
There is also a possibility of a publication bias for suc-Suggested tests include a complete blood count (CBC)
cessful reports. Unfortunately, RPGN is an uncommonwith total and differential white blood cell (WBC) count,
condition with extremely poor prognosis, and these twoperipheral smear, chest x-ray, blood cultures in selected
factors make it very difficult to perform prospective con-cases, C3, C4 and total complement, ANA and anti-DNA
trolled trials with an adequate number of patients. As-antibodies, hepatitis B and C serology, cryoglobulins,
signing patients to a no-treatment arm may not beanti-GBM antibodies, and ANCA testing.
deemed ethical because of the rapid development ofAlthough clinical presentation and laboratory studies
renal failure. The treatment recommendations for thismay be helpful in the differential diagnosis of suspected
reason will be made on the basis of available data, evenRPGN, the final diagnosis is established on a detailed
though this evidence (level 3 evidence) is not alwaysanalysis of renal pathology by light, immunofluorescence,
and electron microscopy. A detailed discussion of renal based on prospective controlled studies.
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Treatment of anti-glomerular basement degree of renal function impairment and requirement of
dialysis at presentation. Of 30 dialysis-dependent patientsmembrane antibody-induced rapidly
with anti-GBM disease treated with plasma exchangeprogressive glomerulonephritis
and immunosuppression, only four (13%) regained aRecommendation 1. Early diagnosis should be estab-
useful renal function despite a fall in anti-GBM antibod-lished.
ies. Among eight patients with serum creatinine levelsRecommendation 2. Methylprednisolone 7 to 15 mg/kg
greater than 600 mmol/liter at the start of treatment butper day to a maximum of 1 g/day for three days, then
not needing dialysis, four improved. In contrast, renalprednisone 60 mg daily for seven days, and thereafter 45,
function improved in 18 of 21 patients with plasma creati-30, 20, 15, 10, 5 mg for one week each is recommended.
nine of less than 600 mmol/liter.Recommendation 3. A daily 4-liter plasma exchange
Walker et al, in an uncontrolled study of plasmaphere-for albumin for 14 days or until anti-GBM antibody
sis, also reported anuria and a high percentage (moredisappears is recommended. No plasmapheresis should
than 85%) of glomeruli showing crescents were badbe given in patients with anuria and crescents involving
prognostic signs. However, some patients with advancedmore than 85% of the glomeruli, unless there is pulmo-
renal failure improved if they were not anuric [7].nary hemorrhage.
Table 1 provides the summary of studies with level ofRecommendation 4. For patients under 55 years old,
evidence for treatment of anti-GBM antibody disease.3 mg/kg (down to nearest 50 mg) of cyclophosphamide
It seems reasonable to conclude that plasma exchange,should be given for eight weeks. For patients over 55
when used along with immunosuppressive drugs, acceler-years old, 2 mg/kg (down to nearest 50 mg) should be
ates the disappearance of anti-GBM antibodies from thegiven for eight weeks.
circulation and probably improves renal function if insti-Recommendation 5. Treatment may be prolonged if
tuted promptly in patients with milder forms of anti-GBMthe anti-GBM antibody is still detectable (grade B and
nephritis. Some patients with more advanced renal func-C recommendations; Fig. 1).
tion may also respond provided they are not anuric and
Evidence. Before 1975, anti-GBM–induced RPGN was
have favorable features on biopsy. The recommended
associated with very poor prognosis. In 1973, Wilson and replacement fluid with plasmapheresis is albumin be-
Dixon studied 81 patients with anti-GBM nephritis and cause of a lower incidence of complications associated
reported that 89% progressed to end-stage renal disease with the use of albumin as compared with plasma [8].
(ESRD) or death within five years [3]. Most of those This treatment regimen should not be used in anuric
patients had received various combinations of oral ste- patients with anti-GBM nephritis unless they have pul-
roids and cytotoxic drugs. In a small, randomized, con- monary hemorrhage. The anti-GBM antibody levels are
trolled 1985 trial (17 patients) Johnson et al compared often spontaneously reduced over time in a large major-
the effect of plasma exchange (4 liters every three days) ity of such patients.
plus immunosuppression (prednisone and cyclophospha- These recommendations are made despite only levels
mide) to immunosuppression alone on the clinical course 3 to 5 evidence in support of the use of plasma pheresis in
and rate of disappearance of antibodies [4]. Patients anti-GBM antibody-mediated RPGN. As recently stated
treated with plasma exchange had a more rapid disap- by Bolton, the major emphasis is on early diagnosis and
pearance of anti-GBM antibodies and mean serum creat- therapy and use of plasmapheresis can be justified be-
inine value that was less than 50% that of patients receiv- cause of the poor prognosis of untreated cases [9].
ing immunosuppression alone at the end of the study. An algorithmic approach to the management of anti-
Similar results were reported by Simpson et al in a non- GBM mediated RPGN is shown in Figure 1.
randomized, controlled study [5]. Couser reviewed 22
Treatment of pauci-immune crescentic rapidlypublished uncontrolled studies involving 186 patients
progressive glomerulonephritiswith anti-GBM nephritis who received plasma exchange
[1]. His summary suggested a favorable effect of plasma- Recommendation 6. Initial steroid treatment is methyl-
pheresis on pulmonary disease in approximately 90% prednisolone 7 to 15 mg/kg/day to a maximum of 1 g/day 3
and renal disease in about 40% of patients. three days, then prednisone 1 mg/kg/day for one month,
The largest published series come from the Hammer- gradually tapered over the next 6 to 12 months.
smith Hospital [6]. They reported outcome at two months Recommendation 7. Cyclophosphamide should be given
on 59 patients treated with plasma exchange and immuno- either orally at a dose of 2 mg/kg/day adjusted to main-
suppression. When using a daily 4-liter plasma exchange tain the leukocyte count between 3 and 5 thousand/ml
for at least 14 days, 85% of patients were alive after two or intravenously starting at 0.5 g/m2/month and increased
months of follow-up. Forty-one percent progressed to monthly by 0.25 g to a maximum of 1 g/m2 per month. The
ESRD, and 44% retained independent renal function. dose should be adjusted to maintain a nadir of leukocyte
count two weeks post-treatment between 3 and 5 thou-The response to treatment was different according to the
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Fig. 1. Decision tree for crescentic glomerulonephritis on renal biopsy. Treatment with pulse methylprednisone cyclophosphamide and prednisone
should be considered in those cases with crescentic glomerulonephritis and a pauci-immune picture upon immunofluorescence, even if they are
ANCA negative.
sand/ml. Cyclophosphamide should be continued for 6 to treated with various combinations of oral steroids, cyto-
toxic drugs, and anticoagulants. Only 20% demonstrated12 months. Treatment should be given even in advanced
patients. significant clinical improvement, and 80% developed
ESRD [1]. Thus, similar to anti-GBM antibody-mediatedRecommendation 8. Consider plasmapheresis in pa-
tients with lung hemorrhage and those with severe dis- RPGN, review of historical controls suggests a poor prog-
nosis in pauci-immune idiopathic RPGN.ease and no response to conventional therapy.
Recommendation 9. Monitoring for relapse with clini- Following the successful use of pulse steroids in eight
patients with proliferative GN, Bolton treated patientscal follow-up, renal function tests, and ANCA is recom-
mended. with idiopathic RPGN with pulse methylprednisolone.
In 1992, they reported on a total of 21 patients withRecommendation 10. Treatment of relapses should be
similar to original treatment (grade B, recommendations; idiopathic RPGN treated with methylprednisolone at 30
mg/kg body wt on alternate days for total of three dosesFig. 1).
Evidence. In 1988 Couser reviewed the results of treat- [10]. This was followed by oral prednisone starting at 2
mg/kg on alternate days and gradual tapering over 12ment in patients with idiopathic RPGN managed in the
1960s and 1970s. Although these patients may have in- months. A few patients also received cyclophosphamide
at approximately 100 mg/day and dipyridamole at 200cluded some patients with immune complex RPGN, pa-
tients with postinfectious and anti-GBM antibody-medi- mg/day. Sixteen of the 21 patients (76%) receiving pulse
therapy showed an improvement in renal function. Tenated RPGN were excluded. He described 78 patients
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Table 1. Studies on the treatment of anti-glomerular basement membrane (GBM) antibody induced rapidly progressive
glomerulonephritis (RPGN)
Level of Author
evidence [Reference] Study design N Treatment Result
2 Johnson [4] Randomized control 17 Steroids, cyclo Better renal survival with
vs. plasma exchange, steroids, cyclo plasmapheresis
3–4 Simpson [5] Nonrandomized control 20 Steroids, Cyclo, Aza Better renal survival with
vs. Steroids, Cyclo, Aza and plasmapheresis plasmapheresis
4 Hammersmith [6] Uncontrolled case series 59 Steroids, Cyclo plasmapheresis 44% improved renal
function
5 Wilson [3] Uncontrolled case series 81 Steroids1Cytotoxic agents ESRD 85%
Abbreviations are: Cyclo, cyclophosphamide, Aza, azathioprine.
of the 15 patients who received pulse therapy and were at the time of their initial presentation, and their average
receiving dialysis were able to discontinue dialysis. Sev- serum creatinine concentration was 801 6 294 mol/liter.
enty-five percent of patients with 60% or more crescents Of these 23 patients, 17 received treatment, 13 with cyclo-
improved with pulse therapy. phosphamide (6 oral and 7 intravenous) and 4 with corti-
With the realization that many cases with pauci-immune costeroids alone. Nine patients (53%) responded, and
RPGN may, in fact, be cases of renal-limited vasculitis, eight (47%) were treatment resistant. There was no sig-
cytotoxic drugs have increasingly been used in such pa- nificant difference in the ages, serum creatinine concen-
tients. Testing for ANCA has further strengthened the trations, or chronicity or activity indices between the
association of necrotizing crescentic GN and vasculitis. respondent and resistant groups.
Nachman et al have recently reported on their experi- In the same set of patients, prognostic markers for
ence with the treatment of 97 patients with ANCA-asso- patient and renal survival were analyzed by the Cox
ciated microscopic vasculitis with RPGN or ANCA-asso- proportional hazard model [12]. The important variables
ciated necrotizing crescentic nephritis [11]. Most patients for patient death were presentation with pulmonary
received methylprednisolone pulse at 7 mg/kg for three hemorrhage and presence of C ANCA (compared with
consecutive days. Prednisone was then given at 1 mg/kg P ANCA) and treatment with steroids alone (5.56 time
for one month and tapered over several months. Twenty- higher versus combined treatment). The predictors for
five patients received treatment with prednisone alone renal survival were entry serum creatinine value, race
and 72 patients received cyclophosphamide and predni- (African Americans having a worse outcome compared
sone following pulse methyl prednisolone. Cyclophos- with Caucasians), and presence of arteriosclerosis on
phamide was given orally at 2 mg/kg, adjusted for the renal biopsy.
WBC count, and given for 6 to 12 months. Intravenous
Such data support the use of a combination of cyclo-
cyclophosphamide was given at an initial dose of 0.5 g/m2
phosphamide and prednisone following initial pulse meth-once a month and was increased to a maximum of 1.0
ylprednisolone in patients with pauci-immune necrotizingg/m2 once a month and adjusted according to the two-
RPGN. Such therapy is indicated even in patients pre-week leukocyte nadir. Because this was not a randomized
senting with advanced disease and dialysis dependence.controlled trial, multivariate analysis was performed to
The published studies on treatment of idiopathic or pauci-assess treatment response and relapses. Overall, 75 of
immune RPGN with level of evidence are summarizedthe 97 patients (77%) went into remission. Of the 75
in Table 2.responders, 32 patients (43%) remained in long-term re-
mission for a mean follow-up of 44 6 29 months. Twenty-
Role of plasmapheresis in pauci-immune rapidlytwo of the 75 patients who initially responded to treat-
progressive glomerulonephritisment (29%) suffered a relapse that generally occurred
Madore et al have recently reviewed the literature onwithin 18 months from the end of therapy. There was
the role of plasma pheresis in patients with pauci-a significant difference in the remission rate between
immune RPGN [13]. In 26 patients with RPGN, Glo¨ck-corticosteroid-treated patients and cyclophosphamide-
ner et al showed no statistical difference in renal outcometreated patients (56 vs. 89%, P 5 0.003), and further-
of those treated with plasma exchange and immunosup-more, cyclophosphamide-treated patients had three times
pressive treatment compared with immunosuppressiveless risk of experiencing a relapse than did corticosteroid-
therapy alone [14]. Cole et al similarly showed no benefittreated patients (0.32; 95% CI 5 0.12 to 0.84).
A total of 23 patients in this study required dialysis of plasmapheresis over immunosuppressive therapy at
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Table 2. Studies on the treatment of pauci-immune crescentic rapidly progressive glomerulonephritis
Level of Author
evidence [Reference] Study design N Treatment Result
3 Nachman [11] Nonrandomized 97 Pulse steroids followed by oral prednisone Better renal and patient survival
control study vs. Pulse steroids, oral predisone and with cyclophosphamide
cyclophosphamide
5 Lobo [10] Uncontrolled 21 Pulse steroids, oral prednisone, 76% improvement in renal
case series cyclophosphamide function
Table 3. Studies on plasma exchange (PE) in idiopathic rapidly progressive glomerulonephritis (RPGN)
Level of Author Study
evidence [Reference] design N Treatment Result
2 Glockner [14] RCT 26 PE 1cytotoxic No benefit of PE
vs. cytotoxic alone
2 Cole [15] RCT 32 PE 1 steroids1Aza No benefit of PE
vs. steroids 1Aza
2–3 Pusey [16] RCT 48 PE1Aza1 steroids1Cyclo No benefit for entire group. For dialysis-dependent patients
vs. Aza 1 steroids1Cyclo discontinuation of dialysis more on PE 91% vs. 37%
2 Rifle [17] RCT 14 Steroids 1Cyclo1heparin For dialysis-dependent patients discontinuation of dialysis
vs. steroids 1Cyclo1heparin 75%, on PE vs. 0 for controls
2 Mauri [18] RCT 22 Steroids 1Cyclo No benefit of PE
vs. steroids 1Cyclo1PE
Abbreviations are: RCT, randomized control trial; Aza, azathioprine; Cyclo, cyclophosphamide.
1, 3, 6, and 12 months following randomization in 32 postinfectious form of RPGN with crescents seems to
have a better prognosis. A review by Couser of 13 seriespatients with idiopathic RPGN [15].
Pusey et al provided evidence based on subgroup anal- included 76 patients with postinfectious RPGN. Fifty
percent recovered spontaneously without disease-spe-ysis of a larger study suggesting a benefit in patients who
presented with severe (dialysis-dependent) disease [16]. cific therapy, 18% underwent partial recovery, and 32%
developed ESRD [1]. Zent et al reported a relativelyOf the 11 dialysis-dependent patients who were treated
with plasma exchange, 10 recovered sufficient renal func- poorer prognosis for crescentic postinfectious GN in
South Africa [19]. In this small series, they suggestedtion to stop dialysis (mean follow-up 4 months) compared
with only three of the eight conventionally treated pa- some benefit of immunosuppressive treatment. How-
ever, the number of patients treated is too small to maketients. Similar trends were noted in other trials [17, 18].
Madore, Lazarus and Brady concluded that the results strong recommendations. A few patients with true idio-
pathic immune complex crescentic RPGN should beof five randomized trials argue against a role for plasma
exchange in milder forms of pauci-immune RPGN, but treated similarly to those with pauci-immune RPGN.
suggested that there was a potential benefit when the
Management of pathophysiologic consequences oftechnique was used as an adjunct to conventional immu-
glomerular diseasenosuppressive therapy in patients with severe disease
[13]. However, the data are not convincing enough to Hypertension is very common in patients with acute
glomerular disease. This may be caused by intravascularprovide firm recommendations. Table 3 provides a sum-
mary of studies on plasmapheresis in idiopathic RPGN volume expansion. The management therefore involves
measures to reduce intravascular volume. These includealong with the level of evidence.
salt and water restriction and diuretic therapy. If these
Management of immune complex rapidly are not able to reduce the volume effectively, especially
progressive glomerulonephritis in the face of severe oliguria, dialysis and ultrafiltration
are required. Peripheral and pulmonary edema will alsoPatients with immune complex RPGN should be
treated according to their specific underlying condition. benefit from these measures. A variety of vasodilators
are also effective in reducing blood pressure. Angioten-The therapy of crescentic phase of IgA nephropathy,
membranoproliferative GN, and membranous GN is dis- sin-converting enzyme inhibitors may be less effective
because of renin-angiotensin system suppression.cussed elsewhere in this issue and is not repeated. The
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Early dialysis may also be indicated for hyperkalemia ited to endocapillary proliferation, the prognosis is good.
There is a slightly higher incidence of crescent formationthat does not respond to conservative therapy, metabolic
acidosis, and uremic syndrome. and mesangiocapillary and glomerulosclerotic changes
in the adult cases. Because of these changes, the inci-
Follow-up and management for renal insufficiency dence of chronic renal damage may increase with increas-
ing age.Adequate follow-up should be performed with clinical
assessment of disease activity as well as renal function. Treatment with immunosuppressive therapy, includ-
ing steroids, azathioprine, or cyclophosphamide, hasThe role of ANCA testing in follow-up of patients with
pauci-immune RPGN is not clear. Although negative been shown to have no benefit in patients with diffuse
proliferative GN. The best available data come from theANCA is useful, a positive ANCA test without clinical
evidence of recurrent disease may not be a definite indi- Medical Research Council Working party reported in
1971. They evaluated treatment of proliferative GN withcation for starting therapy. This may trigger the need
for a closer follow-up [11, 20]. Treatment for renal insuf- azathioprine and prednisone. Fifty-one adults with pro-
liferative GMN were in the treatment group, and 52 wereficiency with appropriate diet and blood pressure control,
including the use of angiotensin-converting enzyme in- in the control group. Minimum treatment was for eight
weeks, but in over two thirds of the patients, the treat-hibitors, would be indicated as in other patients with
chronic renal insufficiency. Details of such therapy are ment was continued for six months. After a minimum
follow-up of six months, there was no benefit with immu-discussed in the article on conservative therapy for
chronic GN in this issue. Similar to the experience in nosuppressive therapy [26]. Similar results have been
reported by Booth et al [27].transplantation, patients on immunosuppressive drugs
may benefit from Septra prophylaxis to prevent Pneumo- During acute presentations, patients should receive
symptomatic treatment for hypertension and fluid over-cystis carinii pneumonia [21]. Calcium supplements of 1 g
daily along with 800 IU vitamin D should be used to load with salt and fluid restriction, diuretics, and vasodi-
lators.prevent negative calcium balance. Consideration for bis-
During follow-up, hypertension, proteinuria, and renalphosphorates should be given to high-risk patients (post-
function should be assessed. Patients with significant pro-menopausal women) [22–24].
teinuria, hypertension, and/or renal function impairment
should receive appropriate nonspecific therapy to slow
DIFFUSE PROLIFERATIVE down the progressive hemodynamic renal function im-
GLOMERULONEPHRITIS pairment.
There is some difficulty in the definition of this entity.
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